Free Trial

Biomerica (BMRA) Competitors

Biomerica logo
$3.35 -0.16 (-4.56%)
Closing price 05/22/2025 03:58 PM Eastern
Extended Trading
$3.27 -0.08 (-2.39%)
As of 05:49 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

BMRA vs. ITRM, TNYA, NRXP, ELYM, RANI, ALGS, SPRO, LVTX, AKTX, and COEP

Should you be buying Biomerica stock or one of its competitors? The main competitors of Biomerica include Iterum Therapeutics (ITRM), Tenaya Therapeutics (TNYA), NRx Pharmaceuticals (NRXP), Eliem Therapeutics (ELYM), Rani Therapeutics (RANI), Aligos Therapeutics (ALGS), Spero Therapeutics (SPRO), LAVA Therapeutics (LVTX), Akari Therapeutics (AKTX), and Coeptis Therapeutics (COEP). These companies are all part of the "pharmaceutical products" industry.

Biomerica vs.

Biomerica (NASDAQ:BMRA) and Iterum Therapeutics (NASDAQ:ITRM) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, media sentiment, risk, earnings, analyst recommendations, dividends, community ranking, institutional ownership and profitability.

Iterum Therapeutics has a consensus price target of $9.00, indicating a potential upside of 866.60%. Given Iterum Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Iterum Therapeutics is more favorable than Biomerica.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Biomerica
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Iterum Therapeutics
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

22.3% of Biomerica shares are held by institutional investors. Comparatively, 9.2% of Iterum Therapeutics shares are held by institutional investors. 15.0% of Biomerica shares are held by company insiders. Comparatively, 9.2% of Iterum Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Biomerica has a beta of 0.37, meaning that its share price is 63% less volatile than the S&P 500. Comparatively, Iterum Therapeutics has a beta of 2.91, meaning that its share price is 191% more volatile than the S&P 500.

Biomerica has higher revenue and earnings than Iterum Therapeutics. Biomerica is trading at a lower price-to-earnings ratio than Iterum Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Biomerica$5.68M1.50-$5.98M-$2.32-1.44
Iterum TherapeuticsN/AN/A-$24.77M-$0.99-0.94

Iterum Therapeutics received 5 more outperform votes than Biomerica when rated by MarketBeat users. However, 67.82% of users gave Biomerica an outperform vote while only 63.11% of users gave Iterum Therapeutics an outperform vote.

CompanyUnderperformOutperform
BiomericaOutperform Votes
137
67.82%
Underperform Votes
65
32.18%
Iterum TherapeuticsOutperform Votes
142
63.11%
Underperform Votes
83
36.89%

Iterum Therapeutics has a net margin of 0.00% compared to Biomerica's net margin of -100.52%. Iterum Therapeutics' return on equity of 0.00% beat Biomerica's return on equity.

Company Net Margins Return on Equity Return on Assets
Biomerica-100.52% -90.19% -64.54%
Iterum Therapeutics N/A N/A -90.85%

In the previous week, Biomerica and Biomerica both had 1 articles in the media. Biomerica's average media sentiment score of 0.00 equaled Iterum Therapeutics'average media sentiment score.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Biomerica
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Iterum Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

Iterum Therapeutics beats Biomerica on 9 of the 15 factors compared between the two stocks.

Get Biomerica News Delivered to You Automatically

Sign up to receive the latest news and ratings for BMRA and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BMRA vs. The Competition

MetricBiomericaDiagnostic substances IndustryMedical SectorNASDAQ Exchange
Market Cap$8.53M$2.61B$5.33B$8.39B
Dividend YieldN/A0.73%5.21%4.11%
P/E Ratio-9.857.4726.7919.70
Price / Sales1.5035.77393.69121.79
Price / CashN/A15.7538.2534.62
Price / Book8.595.496.774.50
Net Income-$5.98M-$65.73M$3.23B$248.22M
7 Day Performance-7.97%-0.44%0.42%-0.80%
1 Month Performance-8.47%0.30%9.06%11.52%
1 Year Performance-34.88%-15.77%18.55%8.99%

Biomerica Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BMRA
Biomerica
0.1444 of 5 stars
$3.35
-4.6%
N/A-33.8%$8.53M$5.68M-9.8560News Coverage
ITRM
Iterum Therapeutics
1.8386 of 5 stars
$1.01
-1.0%
$9.00
+791.1%
-34.4%$36.04MN/A-0.7710
TNYA
Tenaya Therapeutics
3.4303 of 5 stars
$0.41
-0.7%
$6.25
+1,420.3%
-90.2%$36.01MN/A-0.29110
NRXP
NRx Pharmaceuticals
1.9107 of 5 stars
$2.08
+2.0%
$28.50
+1,270.2%
-31.0%$35.83MN/A-0.972Analyst Upgrade
ELYM
Eliem Therapeutics
N/A$1.19
flat
N/A-84.6%$35.41MN/A-2.259News Coverage
RANI
Rani Therapeutics
2.2543 of 5 stars
$0.61
-16.0%
$12.00
+1,857.6%
-87.6%$35.24M$1.03M-0.58110News Coverage
Analyst Revision
ALGS
Aligos Therapeutics
3.4151 of 5 stars
$5.68
+26.8%
$70.00
+1,132.4%
-65.6%$34.73M$3.27M-0.4390Gap Up
SPRO
Spero Therapeutics
4.1095 of 5 stars
$0.61
-1.6%
$5.00
+719.7%
-53.6%$34.11M$27.40M8.72150Gap Down
LVTX
LAVA Therapeutics
2.0254 of 5 stars
$1.28
+2.3%
$3.17
+147.6%
-53.3%$33.64M$11.98M-1.2460Gap Down
AKTX
Akari Therapeutics
N/A$1.41
+11.9%
N/A-33.2%$33.51MN/A0.009News Coverage
Analyst Forecast
COEP
Coeptis Therapeutics
0.239 of 5 stars
$9.90
+4.2%
N/A+70.4%$33.31MN/A-1.712Analyst Upgrade
Gap Up

Related Companies and Tools


This page (NASDAQ:BMRA) was last updated on 5/23/2025 by MarketBeat.com Staff
From Our Partners